...
首页> 外文期刊>Cell Biology and Toxicology >Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells
【24h】

Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells

机译:半高通量方法在体外和培养细胞中测量蛋白酶体抑制

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The ubiquitin proteasomeaproteolytic pathway has emerged as one of the most significant pathways in modulating protein homeostasis under both normal and disease states. The use of proteasome inhibitors (PI) has played a pivotal role in understanding protein turn over. The main objective of this work was to develop a comprehensive, fast, and reliable, yet simple in vitro assay that would allow for the identification and characterization of a wide range of PIs. The assays consist of a 96-well plate high throughput (HTP) method to assess proteasome activity in Hs578T breast cancer cell extracts, purified 20S proteasome, using a fluorogenic substrate, Suc-leu-leu-val-tyr-7-AMC, specific to the chymotrypsin-like enzymatic activity of the proteasome. We showed that the chymotrypsin-like activity of the proteasome was inhibited in the two in vitro systems, albeit to different degrees. The assay system also includes two cell-based assays consisting of a vector expressing a fusion protein of green fluorescent protein (gfp) and Mouse Ornithine Decarboxylase (MODC) in Zs578T (parental Hs578T carrying the vector that expresses the fusion protein). In the cell-based assay analyses (qualitatively by microscopy and quantitatively by flow cytometry), treatment of Zs578T with PIs prevented the degradation of MODC, accumulated gfp, indicative of increased proteasome inhibition. Because no single assay represents a definitive proof of proteasome inhibitory activity, combined, these assays should serve as a comprehensive benchmark for the identification and partial characterization of novel inhibitors. In summary, the four-step assay protocol can easily be adapted into a high throughput format to rapidly screen unknown inhibitors.
机译:在正常和疾病状态下,遍在蛋白蛋白酶体脂解途径已经成为调节蛋白质稳态的最重要途径之一。蛋白酶体抑制剂(PI)的使用在理解蛋白质转换中起着关键作用。这项工作的主要目的是开发一种全面,快速,可靠但简单的体外测定方法,该方法可用于鉴定和表征各种PI。该测定法由96孔板高通量(HTP)方法组成,用于评估Hs578T乳腺癌细胞提取物,纯化的20S蛋白酶体中的蛋白酶体活性,使用荧光底物Suc-leu-leu-val-tyr-7-AMC,特异性蛋白酶体的胰凝乳蛋白酶样酶活性。我们显示了蛋白酶体的胰凝乳蛋白酶样活性在两个体外系统中均受到抑制,尽管程度不同。该测定系统还包括两个基于细胞的测定,包括在Zs578T中表达绿色荧光蛋白(gfp)和小鼠鸟氨酸脱羧酶(MODC)融合蛋白的载体(父母Hs578T携带表达融合蛋白的载体)。在基于细胞的测定分析中(通过显微镜定性,通过流式细胞术定量),用PI处理Zs578T可以防止MODC降解,积累的gfp,表明蛋白酶体抑制作用增强。由于没有单一的测定方法能够代表蛋白酶体抑制活性的确定证据,因此将这些方法结合起来可以作为鉴定和部分表征新型抑制剂的综合基准。总而言之,可以轻松地将四步测定方案修改为高通量格式,以快速筛选未知抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号